Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06167213
Other study ID # 2021-05-Mitral
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2024
Est. completion date March 2038

Study information

Verified date December 2023
Source Edwards Lifesciences
Contact Edwards THV Clinical Affairs
Phone 949-250-2500
Email THV_CT.gov@edwards.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater surgical risk with a failing mitral surgical bioprosthetic valve or a failing native mitral valve with an annuloplasty ring.


Description:

This is a prospective, single arm, multicenter, pivotal study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 125
Est. completion date March 2038
Est. primary completion date March 2029
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Failing mitral surgical bioprosthetic valve or a failing native mitral valve with an annuloplasty ring demonstrating = moderate stenosis and/or = moderate insufficiency 2. Bioprosthetic surgical valve or native mitral annulus size suitable for SAPIEN X4 THV 3. NYHA functional class = II 4. Heart Team agrees the subject is at high or greater surgical risk 5. The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent. Exclusion Criteria: 1. Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system 2. Interatrial septum or left atrium not suitable for transcatheter transseptal access 3. Failing valve has mild or greater paravalvular regurgitation 4. Failing valve is unstable, rocking, or not structurally intact 5. Annuloplasty ring dehiscence 6. Known severe patient-prosthesis mismatch or bioprosthetic valve with residual mean gradient > 10 mmHg at the end of the index procedure for implantation of the original valve 7. Annuloplasty ring type not favorable for THV implantation 8. Increased risk of THV embolization 9. Anatomical characteristics that would increase risk of left ventricular outflow tract (LVOT) obstruction 10. Surgical or transcatheter aortic valve extending into LVOT that may impinge on the mitral implant 11. Severe right ventricle (RV) dysfunction 12. Severe regurgitation or stenosis of any other valve 13. Need for aortic, tricuspid, or pulmonic valve intervention within the next 12 months 14. Left ventricular ejection fraction < 20% 15. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation 16. Myocardial infarction within 30 days prior to the study procedure 17. Hypertrophic cardiomyopathy with subvalvular obstruction 18. Subjects with planned concomitant ablation for atrial fibrillation 19. Clinically significant coronary artery disease requiring revascularization 20. Any surgical or transcatheter procedure within 30 days prior to the study procedure. Implantation of a permanent pacemaker or implantable cardioverter defibrillator (ICD) is not considered an exclusion. 21. Any planned surgical or transcatheter intervention to be performed within 30 days following the study procedure 22. Endocarditis within 180 days prior to the study procedure 23. Stroke, transient ischemic attack or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to the study procedure 24. Hemodynamic or respiratory instability requiring inotropic or mechanical support within 30 days prior to the study procedure 25. Renal insufficiency and/or renal replacement therapy 26. Leukopenia, anemia, thrombocytopenia 27. Inability to tolerate or condition precluding treatment with antithrombotic therapy 28. Hypercoagulable state or other condition that increases risk of thrombosis 29. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication 30. Subject refuses blood products 31. Body mass index > 50 kg/m2 32. Estimated life expectancy < 24 months 33. Female who is pregnant or lactating 34. Active SARS-CoV-2 infection or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments 35. Participating in another investigational drug or device study that has not reached its primary endpoint 36. Subject considered to be part of a vulnerable population

Study Design


Intervention

Device:
SAPIEN X4 THV
Implantation of the SAPIEN X4 valve

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Edwards Lifesciences

Outcome

Type Measure Description Time frame Safety issue
Primary Non-hierarchical composite of death and stroke at 1 year The number of patients that died or had a stroke 1 year
Secondary Kansas City Cardiomyopathy Questionnaire (KCCQ) score compared to baseline The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains.
Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
30 days
Secondary Kansas City Cardiomyopathy Questionnaire (KCCQ) score compared to baseline The KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains.
Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
1 year
Secondary New York Heart Association (NYHA) functional class compared to baseline NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. 30 days
Secondary New York Heart Association (NYHA) functional class compared to baseline NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort. 1 year
See also
  Status Clinical Trial Phase
Completed NCT03278574 - Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease N/A
Suspended NCT04960280 - A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease N/A
Recruiting NCT05021614 - Valveclip® Transcatheter Mitral Valve Repair Study N/A
Not yet recruiting NCT06465745 - AltaValve Pivotal Trial N/A
Withdrawn NCT05040451 - Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
Withdrawn NCT03714412 - Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System N/A
Recruiting NCT02592889 - (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Phase 4
Completed NCT02355418 - The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
Not yet recruiting NCT01431222 - Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Phase 4
Completed NCT01841554 - Cardioband With Transfemoral Delivery System N/A
Not yet recruiting NCT03870516 - Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery N/A
Active, not recruiting NCT03230747 - SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation N/A
Enrolling by invitation NCT04031274 - Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
Completed NCT05836532 - Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
Completed NCT05836480 - Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
Completed NCT05850026 - Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Recruiting NCT03975998 - Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
Completed NCT01162083 - Identifying an Ideal Cardiopulmonary Exercise Test Parameter N/A
Suspended NCT00787293 - Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients Phase 2
Recruiting NCT00745680 - Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI) N/A